Transcription-based drug repurposing for COVID-19

Richard Killick; Clive Ballard; Patrick Doherty; Gareth Williams

doi:10.1016/j.virusres.2020.198176

Transcription-based drug repurposing for COVID-19

Richard Killick, Clive Ballard, Patrick Doherty, Gareth Williams^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.

Original language	English
Article number	198176
Journal	Virus Research
Volume	290
DOIs	https://doi.org/10.1016/j.virusres.2020.198176
Publication status	Published - Dec 2020

Keywords

COVID-19
Gene expression
Repurposing

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.virusres.2020.198176

Cite this

@article{d2c67218af6d4435bb88e548c78c41d4,

title = "Transcription-based drug repurposing for COVID-19",

abstract = "We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.",

keywords = "COVID-19, Gene expression, Repurposing",

author = "Richard Killick and Clive Ballard and Patrick Doherty and Gareth Williams",

year = "2020",

month = dec,

doi = "10.1016/j.virusres.2020.198176",

language = "English",

volume = "290",

journal = "Virus Research",

issn = "0168-1702",

publisher = "Elsevier",

}

TY - JOUR

T1 - Transcription-based drug repurposing for COVID-19

AU - Killick, Richard

AU - Ballard, Clive

AU - Doherty, Patrick

AU - Williams, Gareth

PY - 2020/12

Y1 - 2020/12

N2 - We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.

AB - We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti−COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.

KW - COVID-19

KW - Gene expression

KW - Repurposing

UR - http://www.scopus.com/inward/record.url?scp=85092073153&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2020.198176

DO - 10.1016/j.virusres.2020.198176

M3 - Article

C2 - 32987033

AN - SCOPUS:85092073153

SN - 0168-1702

VL - 290

JO - Virus Research

JF - Virus Research

M1 - 198176

ER -

Transcription-based drug repurposing for COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this